ImmuneOncia Therapeutics, Inc. Q3 operating loss of KRW 9.1 billion with no revenue
ImmuneOncia Therapeutics, Inc.· Periodic Report
AI summary · Not investment advice
Immuneoncia had no sales in the third quarter and lost KRW 9.1 billion from its main business, versus a KRW 10.6 billion loss a year earlier.
Operating profit · 3 months
KRW -9.1 billion
Key facts
- Revenue (3 months)
- KRW 0
- Net income (3 months)
- KRW -8.1 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 0
- Revenue (year to date)
- KRW 0
- Operating profit (prior-year 3 months)
- KRW -10.6 billion
- Operating profit (year to date)
- KRW -19.2 billion
- Net income (prior-year 3 months)
- KRW -10.4 billion
- Net income (year to date)
- KRW -17.6 billion
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
I